Takeda to sell OTC drug business to US private equity firm for $2.37B

Japan-based Takeda Pharmaceutical will sell its over-the-counter drug business to Blackstone Group, a U.S. private equity firm, for $2.37 billion, according to the Nikkei Asian Review.

Advertisement
Maia Anderson

The drugmaker incurred debt when it acquired Shire, a U.K.-based drugmaker, in 2019, and the sale of its nonprescription drug division is intended to relieve some of that debt.  

Takeda will focus its management resources on developing prescription drugs, the company told the Nikkei Asian Review. It plans to sell a total of $10 billion in assets. 

Read the full article here. 

More articles on pharmacy:
FDA halts approval of blood plasma as COVID-19 treatment
J&J to acquire Momenta Pharma for $6.5B
US sues Teva for alleged MS drug kickback scheme

How 3 systems are improving patient flow and workforce alignment at infusion centers

Recommended Whitepaper

Advertisement

Next Up in Pharmacy

  • 75 drugs currently in shortage: FDA

    The number of active drug shortages has declined sharply since June, according to the FDA’s drug shortage database. Seventy-five drugs…

    By: Mackenzie Bean

  • 6 recent updates on GLP-1 drugs

    From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December.…

    By: Ella Jeffries

  • 73 drugs lost exclusivity in 2025

    In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval…

    By: Paige Twenter
Advertisement

Comments are closed.